Phase II study of docetaxel (taxotere) in patients with previously untreated extensive small cell lung cancer
- 56 Downloads
The objective of this multicenter phase II study was to evaluate the activity of docetaxel in previously untreated small cell lung cancer. Fourteen patients were treated at a dose of 75 mg/m2 intravenously every three weeks. Of the 12 patients evaluable for response, one had a partial response for a duration of 12 weeks for a response rate of 8.3%. Toxicity was mild. We conclude that docetaxel has, at the dose given in this study, little activity in previously untreated small cell lung cancer.
Key wordsphase II study docetaxel small cell lung cancer
Unable to display preview. Download preview PDF.
- 3.Ettinger DS, Finkelstein DM, Sarma R, Johnson DH: Phase II study of Taxol in patients with extensive-stage small cell lung cancer: An Eastern Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 12:329, 1993Google Scholar
- 4.Kirschling RJ, Jung SH, Jett JR: A phase II trial of taxol and GCSF in previously untreated patients with extensivestage small cell lung cancer. Proc Am Soc Clin Oncol 13: 326, 1994Google Scholar